Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Signs and Symptoms, Digestive

ClinicalTrials.gov lists 5,022 trials for Signs and Symptoms, Digestive or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 36.

MeSH D012817 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 221 Phase 1/2 Phase 1/2 82 Phase 2 Phase 2 470 Phase 2/3 Phase 2/3 101 Phase 3 Phase 3 545 Phase 4 Phase 4 554 Not applicable Not applicable 2,160 Observational Observational 882 Phase 1 Phase 1 221 Phase 1/2 Phase 1/2 82 Phase 2 Phase 2 470 Phase 2/3 Phase 2/3 101 Phase 3 Phase 3 545 Phase 4 Phase 4 554 Not applicable Not applicable 2,160 Observational Observational 882

Trials per phase (log scale)

1 more section with rows

29 of the 5,022 trials are tagged with Signs and Symptoms, Digestive itself; the rest are tagged with a narrower condition beneath it.

Get the Signs and Symptoms, Digestive report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Signs and Symptoms, Digestive trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 308

1993: 1 trials (Not applicable 1) 1994: 3 trials (Phase 3 1, Phase 2 1, Phase 1/2 1) 1995: 4 trials (Observational 1, Phase 4 1, Phase 2 2) 1996: 6 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 2) 1997: 8 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 1) 1998: 14 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 6, Phase 1/2 1, Phase 1 2) 1999: 14 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2 4) 2000: 16 trials (Observational 2, Not applicable 3, Phase 4 2, Phase 3 6, Phase 1/2 2, Phase 1 1) 2001: 22 trials (Observational 3, Not applicable 9, Phase 4 2, Phase 3 5, Phase 2 3) 2002: 37 trials (Observational 3, Not applicable 7, Phase 4 12, Phase 3 9, Phase 2 4, Phase 1/2 1, Phase 1 1) 2003: 56 trials (Observational 5, Not applicable 12, Phase 4 16, Phase 3 6, Phase 2/3 4, Phase 2 9, Phase 1 4) 2004: 89 trials (Observational 8, Not applicable 19, Phase 4 11, Phase 3 24, Phase 2/3 2, Phase 2 17, Phase 1 8) 2005: 122 trials (Observational 19, Not applicable 28, Phase 4 12, Phase 3 28, Phase 2/3 2, Phase 2 17, Phase 1/2 4, Phase 1 12) 2006: 138 trials (Observational 17, Not applicable 24, Phase 4 21, Phase 3 31, Phase 2/3 4, Phase 2 26, Phase 1/2 4, Phase 1 11) 2007: 133 trials (Observational 15, Not applicable 27, Phase 4 27, Phase 3 24, Phase 2/3 6, Phase 2 21, Phase 1/2 2, Phase 1 11) 2008: 156 trials (Observational 28, Not applicable 42, Phase 4 25, Phase 3 30, Phase 2/3 6, Phase 2 15, Phase 1/2 3, Phase 1 7) 2009: 185 trials (Observational 26, Not applicable 48, Phase 4 32, Phase 3 29, Phase 2/3 3, Phase 2 30, Phase 1/2 2, Phase 1 15) 2010: 201 trials (Observational 32, Not applicable 55, Phase 4 25, Phase 3 31, Phase 2/3 7, Phase 2 34, Phase 1/2 6, Phase 1 11) 2011: 188 trials (Observational 27, Not applicable 53, Phase 4 25, Phase 3 36, Phase 2/3 7, Phase 2 25, Phase 1/2 3, Phase 1 12) 2012: 204 trials (Observational 33, Not applicable 78, Phase 4 27, Phase 3 25, Phase 2/3 4, Phase 2 24, Phase 1/2 4, Phase 1 9) 2013: 201 trials (Observational 33, Not applicable 76, Phase 4 27, Phase 3 27, Phase 2/3 2, Phase 2 18, Phase 1/2 8, Phase 1 10) 2014: 199 trials (Observational 28, Not applicable 92, Phase 4 23, Phase 3 20, Phase 2/3 5, Phase 2 22, Phase 1 9) 2015: 221 trials (Observational 43, Not applicable 92, Phase 4 23, Phase 3 23, Phase 2/3 6, Phase 2 24, Phase 1/2 1, Phase 1 9) 2016: 207 trials (Observational 54, Not applicable 77, Phase 4 27, Phase 3 21, Phase 2/3 2, Phase 2 16, Phase 1/2 3, Phase 1 7) 2017: 212 trials (Observational 39, Not applicable 102, Phase 4 27, Phase 3 18, Phase 2/3 5, Phase 2 12, Phase 1/2 2, Phase 1 7) 2018: 222 trials (Observational 45, Not applicable 107, Phase 4 23, Phase 3 14, Phase 2/3 5, Phase 2 18, Phase 1/2 3, Phase 1 7) 2019: 230 trials (Observational 50, Not applicable 108, Phase 4 32, Phase 3 14, Phase 2/3 3, Phase 2 19, Phase 1/2 1, Phase 1 3) 2020: 233 trials (Observational 57, Not applicable 105, Phase 4 28, Phase 3 13, Phase 2/3 2, Phase 2 16, Phase 1/2 3, Phase 1 9) 2021: 243 trials (Observational 48, Not applicable 134, Phase 4 18, Phase 3 17, Phase 2/3 2, Phase 2 11, Phase 1/2 4, Phase 1 9) 2022: 272 trials (Observational 61, Not applicable 144, Phase 4 17, Phase 3 16, Phase 2/3 8, Phase 2 17, Phase 1/2 2, Phase 1 7) 2023: 278 trials (Observational 47, Not applicable 180, Phase 4 15, Phase 3 12, Phase 2/3 2, Phase 2 9, Phase 1/2 5, Phase 1 8) 2024: 308 trials (Observational 63, Not applicable 186, Phase 4 9, Phase 3 24, Phase 2/3 4, Phase 2 12, Phase 1/2 3, Phase 1 7) 2025: 297 trials (Observational 50, Not applicable 173, Phase 4 19, Phase 3 12, Phase 2/3 6, Phase 2 18, Phase 1/2 8, Phase 1 11)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 249
2025 297
2024 308
2023 278
2022 272
2021 243
2020 233
2019 230
2018 222
2017 212

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 300 trials starting in 2026 and about 300 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 33 months from start to primary completion across 313 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 3,406 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Signs and Symptoms, Digestive trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 221
Phase 1/2 82
Phase 2 470
Phase 2/3 101
Phase 3 545
Phase 4 554
Not applicable 2,160
Observational 882
Expanded access 7

How many Signs and Symptoms, Digestive trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 207
Recruiting 403
Enrolling by invitation 36
Active, not recruiting 110
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Signs and Symptoms, Digestive trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 36
Bausch Health Americas, Inc. 33
GlaxoSmithKline 33
Merck Sharp & Dohme LLC 31
Novartis 21

Which drugs are being tested for Signs and Symptoms, Digestive? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Aprepitant 88
GRANISETRON 49
DEXMEDETOMIDINE 24
Naloxegol 23

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 160
Ondansetron - Parts A + B 160
I.V. palonosetron 65
IM olanzapine 43
Nexium Pill 40

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Signs and Symptoms, Digestive trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
All Fractures 860 1
Febrile neutropenia 482 22
Pneumonia 342 78
Neutropenia 244 30
Severe hypoglycemia 237 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (19)

MeSH descendants one level down with at least one trial, most trials first.

+9 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages